Evidence map›Paper›PMID 26056688›Full record

ReviewChemical Society reviews2015

Development of individualized anti-metastasis strategies by engineering nanomedicines.

Qianjun He, Shengrong Guo, Zhiyong Qian, Xiaoyuan Chen

Abstract readReview
In one paragraph

Review in Chemical Society reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
8.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 127 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Photoacid Generators for Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  6. Review
  7. Aptamer-functionalized polydiacetylene biosensor for the detection of three foodborne pathogens.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Metastatic disease in head & neck oncology.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2020
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Qianjun HeState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, P. R. China. nanoflower@126.com.
Shengrong GuoSchool of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, P. R. China.
Zhiyong QianState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, P. R. China. nanoflower@126.com.
Xiaoyuan ChenLaboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892, USA. shawn.chen@nih.gov.
Chengdu University · CNNational Institute of Biomedical Imaging and Bioengineering · USShanghai Jiao Tong University · CNSichuan University · CN

Funding

Laboratory of Molecular Imaging and NanomedicineZIAEB000073 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI CHEN, XIAOYUAN · 2010 to 2020
$32.8M
Intramural NIH HHS ZIA EB000073
6 · The paper itself

Abstract

Metastasis is deadly and also tough to treat as it is much more complicated than the primary tumour. Anti-metastasis approaches available so far are far from being optimal. A variety of nanomedicine formulae provide a plethora of opportunities for developing new strategies and means for tackling metastasis. It should be noted that individualized anti-metastatic nanomedicines are different from common anti-cancer nanomedicines as they specifically target different populations of malignant cells. This review briefly introduces the features of the metastatic cascade, and proposes a series of nanomedicine-based anti-metastasis strategies aiming to block each metastatic step. Moreover, we also concisely introduce the advantages of several promising nanoparticle platforms and their potential for constructing state-of-the-art individualized anti-metastatic nanomedicines.

Indexed as

Antineoplastic AgentsBiological AvailabilityDrug Delivery SystemsHumansImmunotherapyNanomedicineNanoparticlesNeoplasm MetastasisNeoplastic Cells, CirculatingPrecision MedicineAntineoplastic Agents

Identifiers

PMID26056688
PMCPMC4540626
OpenAlexW2141690509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.